The Special AT-rich Sequence Binding Protein 1 (SATB1) and its role in solid tumors

Frömberg, Anja; Engeland, Kurt; Aigner, Achim

doi:10.1016/j.canlet.2017.12.031

Cited by 25 publications

(30 citation statements)

References 191 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since the discovery of SATB1, its role in the pathogenesis of various cancers has been investigated. Importantly, upregulation of SATB1 has been shown to promote many pathological features across a wide range of cancers [38,39] including breast [1,[40][41][42], colorectal [2,[43][44][45], lung [46,47], nasopharyngeal [48], oesophageal [3,49,50], gastric [51,52], pancreatic [53,54], ovarian [32,55,56], liver [57][58][59], prostate [60][61][62][63], bladder [64,65], and brain [66][67][68][69][70]. In most cancers, the SATB1 expression is positively associated with increased tumour size, lymph node involvement and metastasis [71,72], tumour progression [1,2], poor prognosis [50,56] and reduced overall survival [49,54].…”

Section: Satb1 and Cancermentioning

confidence: 99%

Functional relevance of SATB1 in immune regulation and tumorigenesis

Sunkara

Gupta

Hansbro

et al. 2018

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

The Special AT-rich Sequence Binding Protein 1 (SATB1) is a chromatin organiser and transcription factor which regulates numerous cellular processes such as differentiation, proliferation and apoptosis through effects on gene expression. SATB1 undergoes various post-translational modifications, which determine its interaction with co-activators and co-repressors to induce regulation of gene transcription. SATB1 is an identified oncogene, its increased expression is associated with poor prognosis in many cancers. This paper provides a review on SATB1-mediated immune responses and on its target genes in the context of tumorigenesis and tumour progression. Specifically, we discuss the role of SATB1 in tumour immunity, Epithelial to Mesenchymal Transition (EMT), metastasis and multidrug resistance. Therapeutic targeting of aberrant SATB1 may be an important strategy in the treatment of cancer.

show abstract

Section: Satb1 and Cancermentioning

confidence: 99%

Functional relevance of SATB1 in immune regulation and tumorigenesis

Sunkara

Gupta

Hansbro

et al. 2018

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

show abstract

“…This is in line with the notion of SATB1 affecting the expression of many genes, as to be readily expected from its broader molecular mechanism(s) of action as chromatin organizer and as shown previously in other tumor entities. SATB1 has been shown previously in other tumor entities to influence the expression of HER receptor family members which were sometimes, but not always, found affected by SATB1 overexpression or inhibition ( 15,29,30 ; see 17 for review). Targeting the HER receptor family is already in practice for treatment of HNSCCs 34 .…”

Section: Discussionmentioning

confidence: 93%

“…In adults, different physiological functions have been described, including its role in the maintenance of pluripotency of hematopoietic stem cells in the bone marrow 14 . SATB1 has been found to be upregulated in various solid tumors including HNSCC, and its role in cancer progression has thus been studied in different tumor entities in great detail ( 15 ; see 16,17 for review). On the other hand, the analysis of TCGA (The Cancer Genome Atlas) expression data via UALCAN 18 does not support SATB1 upregulation in solid tumors including HNSCC.…”

mentioning

confidence: 99%

SATB1 as oncogenic driver and potential therapeutic target in head & neck squamous cell carcinoma (HNSCC)

Panchal

Wichmann

Grénman

et al. 2020

Sci Rep

Self Cite

View full text Add to dashboard Cite

The Special AT-rich sequence binding protein 1 (SATB1) is a genome organizer protein that controls gene expression of numerous genes by regulating chromatin architecture and targeting chromatinremodeling/-modifying enzymes onto specific chromatin regions. SATB1 is overexpressed in various tumors. In head and neck squamous cell carcinoma (HNSCC), SATB1 upregulation is correlated with TNM classification, metastasis, poor prognosis and reduced overall survival. In this paper, we comprehensively analyze cellular and molecular effects of SATB1 in a large set of primary cell lines from primary HNSCC or metastases, using RNAi-mediated knockdown in vitro and, therapeutically, in tumor xenograft mouse models in vivo. In a series of 15 cell lines, major differences in SATB1 levels are observed. In various 2-D and 3-D assays, growth inhibition upon efficient siRNA-mediated SATB1 knockdown depends on the cell line rather than initial SATB1 levels. Inhibitory effects are found to be based on cell cycle deceleration, apoptosis induction, decreased HER3 and Heregulin A&B expression, and effects on EMT genes. In vivo, systemic treatment of tumor xenograft-bearing mice with siRNAs formulated in polymeric nanoparticles inhibits tumor growth of two HNSCC xenograft models, resulting from therapeutic SATB1 reduction and concomitant decrease of proliferation and induction of apoptosis. In conclusion, SATB1 represents a promising target in HNSCC, affecting crucial cellular processes and molecular pathways.

show abstract

“…The data revealed that high expression level of SATB1 was correlated with decreased tumor differentiation, distant metastasis and lymph node metastasis in CRC, indicating its important role in tumor progression and its possible use as a tumor marker. Up to date, many studies have explored the oncogenic mechanism of SATB1 in cancers, high expectations can be hold that SATB1 may be a novel tumor antigen (Frömberg et al, 2018 ).…”

Section: Discussionmentioning

confidence: 99%

“…An increasing number of publications reveal that SATB1 expression in CRC is associated to the expression of β-catenin (Nodin et al, 2012 ), cyclin D1, MMP2, NF-kB, PCNA (Zhang et al, 2013 ) and S100A4 (Niu et al, 2015 ). Consequently, a great number of studies demonstrate that SATB1 is a biomarker that can predict poor progress for CRC patients (Brocato and Costa, 2015 ; Frömberg et al, 2018 ). In the present study, we aim to explore the association between the expression level of SATB1 and CRC clinical outcomes by quantitatively performing meta-analysis.…”

Section: Introductionmentioning

confidence: 99%

Prognostic and Clinicopathological Significance of SATB1 in Colorectal Cancer: A Meta-Analysis

et al. 2018

View full text Add to dashboard Cite

Background: A large number of studies have reported the aberrant expression of special AT-rich sequence binding protein 1 (SATB1) in colorectal cancer (CRC). However, the role of SATB1 in CRC is still controversial. Therefore, we performed this meta-analysis to elucidate the prognostic and clinical value of SATB1 in CRC patients.Methods: We searched Web of Science, EMBASE and PubMed entirely in January 2018 to identify related articles. Pooled Hazard ratio (HR) was adopted to evaluate the prognostic value of SATB1 in CRC and odd ratio (OR) was used to assess the clinicopathological significance of SATB1 in CRC.Results: Ten eligible studies containing 7 on prognosis and 9 on clinicopathological characteristics were finally included in the present meta-analysis. Results revealed that patients with high expression of SATB1 tended to have shorter overall survival (OS) (pooled HR: 1.64, 95% CI: 1.04–2.57). Besides, we also discovered that the expression of SATB1 was associated with histologic grade (OR = 1.88, 95% CI: 1.06–3.34), distant metastasis (OR = 1.43, 95% CI: 1.11–1.85) and lymph node metastasis (OR = 1.50, 95% CI: 1.03–2.19).Conclusion: Broadly speaking, our meta-analysis demonstrated that high expression level of SATB1 was related to poor prognosis in CRC patients.

show abstract

The Special AT-rich Sequence Binding Protein 1 (SATB1) and its role in solid tumors

Cited by 25 publications

References 191 publications

Functional relevance of SATB1 in immune regulation and tumorigenesis

Functional relevance of SATB1 in immune regulation and tumorigenesis

SATB1 as oncogenic driver and potential therapeutic target in head & neck squamous cell carcinoma (HNSCC)

Prognostic and Clinicopathological Significance of SATB1 in Colorectal Cancer: A Meta-Analysis

Contact Info

Product

Resources

About